Kalaris Financial Statements From 2010 to 2025

KLRS Stock   9.58  0.08  0.83%   
Kalaris Therapeutics,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kalaris Therapeutics,'s valuation are provided below:
Market Capitalization
45.3 M
Earnings Share
(2.71)
There are over one hundred available fundamental ratios for Kalaris Therapeutics,, which can be analyzed over time and compared to other ratios. All traders should check Kalaris Therapeutics,'s last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 48 M in 2025, whereas Enterprise Value is likely to drop (76.2 M) in 2025.
Check Kalaris Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalaris Therapeutics,'s main balance sheet or income statement drivers, such as Total Revenue of 0.0, Other Operating Expenses of 55.9 M or Research Development of 11.7 M, as well as many indicators such as Price To Sales Ratio of 71.68, Dividend Yield of 0.0 or PTB Ratio of 0.42. Kalaris financial statements analysis is a perfect complement when working with Kalaris Therapeutics, Valuation or Volatility modules.
  
Build AI portfolio with Kalaris Stock
Check out the analysis of Kalaris Therapeutics, Correlation against competitors.
For more information on how to buy Kalaris Stock please use our How to Invest in Kalaris Therapeutics, guide.

Kalaris Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets108.3 M118.5 M78.7 M
Slightly volatile
Other Current Liabilities5.4 MM3.7 M
Slightly volatile
Total Current Liabilities8.9 M5.2 M7.3 M
Slightly volatile
Current Deferred Revenue2.1 M2.4 M2.6 M
Slightly volatile
Accounts Payable234.7 K247 K1.1 M
Slightly volatile
Cash84.1 M118.3 M51.2 M
Slightly volatile
Non Currrent Assets Other1.3 M1.3 M510.1 K
Slightly volatile
Cash And Short Term Investments100.6 M118.3 M73.8 M
Slightly volatile
Net Receivables42.8 K45 K247.9 K
Slightly volatile
Common Stock Shares Outstanding3.5 MMM
Slightly volatile
Liabilities And Stockholders Equity108.3 M118.5 M78.7 M
Slightly volatile
Other Current Assets244.2 K257 K772.6 K
Slightly volatile
Other Stockholder Equity869.8 M828.4 M169.7 M
Slightly volatile
Total LiabilitiesM5.2 M14 M
Slightly volatile
Total Current Assets102.1 M118.5 M74.9 M
Slightly volatile
Short and Long Term Debt Total2.8 M2.9 M10.5 M
Slightly volatile
Property Plant And Equipment Net19.4 M36 M17.5 M
Slightly volatile
Short Term Investments39.7 M41.8 M69 M
Very volatile
Non Current Liabilities Total53.6 M51.1 M18.3 M
Slightly volatile
Short Term Debt4.7 M7.6 M4.1 M
Slightly volatile
Common Stock5.6 K6.3 K6.9 K
Slightly volatile
Long Term Debt2.6 M2.9 M3.2 M
Slightly volatile

Kalaris Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses55.9 M55.3 M28.1 M
Slightly volatile
Research Development11.7 M12.3 M15.5 M
Slightly volatile
Total Operating Expenses55.7 M55.3 M28 M
Slightly volatile
Depreciation And Amortization1.3 M1.3 M390.5 K
Slightly volatile
Cost Of Revenue654.5 K1.3 M380.8 K
Slightly volatile
Income Tax Expense805.6 K906.3 K988.1 K
Slightly volatile
Interest Expense507.1 K790 K314.9 K
Slightly volatile
Selling General Administrative1.6 M1.6 M2.1 M
Slightly volatile

Kalaris Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Cash26.6 M28.2 M28.7 M
Very volatile
Other Non Cash Items12.3 M16.4 M6.1 M
Slightly volatile
Total Cash From Financing Activities19.9 K21 K40.4 M
Very volatile
End Period Cash Flow84.1 M118.3 M51.2 M
Slightly volatile
Begin Period Cash Flow55.4 M90.1 M36.4 M
Slightly volatile
Depreciation1.3 M1.3 M390.5 K
Slightly volatile
Net Borrowings5.7 M6.9 M4.7 M
Slightly volatile
Stock Based Compensation167.6 K133.2 K248.2 K
Slightly volatile
Other Cashflows From Financing Activities6.7 M7.4 M8.3 M
Slightly volatile
Issuance Of Capital Stock6.1 M6.1 M8.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio71.6814174.9701
Slightly volatile
Days Sales Outstanding1.2 K1.1 K585
Slightly volatile
Capex To Depreciation0.02540.026811.3601
Slightly volatile
Payables Turnover0.080.120.0897
Slightly volatile
Research And Ddevelopement To Revenue92.9588.5242.9211
Slightly volatile
Capex To Revenue1.641.852.0159
Slightly volatile
Cash Per Share22.4423.617735.6392
Pretty Stable
Days Payables Outstanding2.2 K2.5 K2.7 K
Slightly volatile
Current Ratio12.7322.62769.2447
Slightly volatile
Receivables Turnover0.320.342.2474
Slightly volatile
Capex Per Share0.01040.0110.0905
Slightly volatile
Revenue Per Share0.06370.0670.2519
Slightly volatile
Interest Debt Per Share0.560.594.0173
Pretty Stable
Debt To Assets0.790.750.2613
Slightly volatile
Operating Cycle1.2 K1.1 K585
Slightly volatile
Days Of Payables Outstanding2.2 K2.5 K2.7 K
Slightly volatile
Ebt Per Ebit0.781.06360.8125
Slightly volatile
Quick Ratio12.7322.62769.2447
Slightly volatile
Net Income Per E B T0.810.910.9877
Slightly volatile
Cash Ratio23.7122.57858.1097
Slightly volatile
Days Of Sales Outstanding1.2 K1.1 K585
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.027
Slightly volatile
Fixed Asset Turnover0.01090.01230.0134
Slightly volatile
Debt Ratio0.790.750.2613
Slightly volatile
Price Sales Ratio71.6814174.9701
Slightly volatile
Asset Turnover0.00130.00140.0258
Slightly volatile

Kalaris Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap48 M45.7 M25.7 M
Pretty Stable

Kalaris Fundamental Market Drivers

About Kalaris Therapeutics, Financial Statements

Kalaris Therapeutics, shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Kalaris Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Kalaris Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Kalaris Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.4 M2.1 M
Cost Of Revenue1.3 M654.5 K
Research And Ddevelopement To Revenue 88.52  92.95 
Capex To Revenue 1.85  1.64 
Revenue Per Share 0.07  0.06 
Ebit Per Revenue(186.10)(176.79)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kalaris Stock Analysis

When running Kalaris Therapeutics,'s price analysis, check to measure Kalaris Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalaris Therapeutics, is operating at the current time. Most of Kalaris Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Kalaris Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalaris Therapeutics,'s price. Additionally, you may evaluate how the addition of Kalaris Therapeutics, to your portfolios can decrease your overall portfolio volatility.